Phase III Clinical Trial, long term treatment with TO-204 - Subcutaneous immunotherapy in patients with HDM-sensitized allergic rhinitis and asthma -

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221855

Enrollment

Registered

2012-07-12

Start date

2012-07-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis or asthma sensitized to house dust mite

Interventions

investigational material(s) Generic name etc : TO-204 INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Positive test in RAST(specific anti-HDM IgE >= Class 2) 2) Positive skin prick/scratch test against HDM allergen

Exclusion criteria

Exclusion criteria: 1) Patients with clinical symptoms of perennial rhinitis or asthma caused by allergen other than HDM 2) Patients with severe asthma 3) Patients with severe systemic diseases (i.e., auto-immune disease, immunocomplex disease, immunodeficient disease)

Design outcomes

Primary

Measure	Time frame
Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026